Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis

Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit−risk profile. https://bit.ly/3SbisW3

Detalles Bibliográficos
Autores principales: Chalmers, James D., Metersky, Mark L., Feliciano, Joseph, Fernandez, Carlos, Teper, Ariel, Maes, Andrea, Hassan, Mariam, Chatterjee, Anjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152260/
https://www.ncbi.nlm.nih.gov/pubmed/37143828
http://dx.doi.org/10.1183/23120541.00695-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152260/
https://www.ncbi.nlm.nih.gov/pubmed/37143828
http://dx.doi.org/10.1183/23120541.00695-2022

Ejemplares similares